Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

Ina Tesseur; Adrian C Lo; Anouk Roberfroid; Sofie Dietvorst; Bianca Van Broeck; Marianne Borgers; Harrie Gijsen; Diederik Moechars; Marc Mercken; John Kemp; Rudi D'Hooge; Bart De Strooper

doi:10.1126/science.1233937

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

Science. 2013 May 24;340(6135):924-e. doi: 10.1126/science.1233937.

Authors

Ina Tesseur¹, Adrian C Lo, Anouk Roberfroid, Sofie Dietvorst, Bianca Van Broeck, Marianne Borgers, Harrie Gijsen, Diederik Moechars, Marc Mercken, John Kemp, Rudi D'Hooge, Bart De Strooper

Affiliation

¹ VIB Center for the Biology of Disease, Leuven, Belgium.

PMID: 23704554
DOI: 10.1126/science.1233937

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) tested bexarotene as a potential β-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Alzheimer Disease / drug therapy*
Alzheimer Disease / metabolism*
Amyloid beta-Peptides / metabolism*
Animals
Apolipoproteins E / metabolism*
Brain / metabolism*
Male
Tetrahydronaphthalenes / pharmacology*
Tetrahydronaphthalenes / therapeutic use*

Substances

Amyloid beta-Peptides
Apolipoproteins E
Tetrahydronaphthalenes